Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -68.17% is in line with its 5-year average of -70.32%, around the middle of its 5-year range (-215.46%–37.34%).
As of the fiscal period ended Tuesday, June 30, 2026. 43.47% above its 12-month average of -120.59%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -68.17%.
RETURN ON EQUITY (ROE)
-68.17%
RETURN ON EQUITY (ROE) AVG TTM
-120.59%
RETURN ON EQUITY (ROE) AVG 3Y
-82.59%
RETURN ON EQUITY (ROE) AVG 5Y
-70.32%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+43.47%
CURRENT VS 3Y AVG
+17.46%
CURRENT VS 5Y AVG
+3.05%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-62.28%
vs the sector median at left
XORTX Therapeutics Inc.
Market Cap
$490141.00
Return on Equity (ROE)
-68.17%
TTM Avg
-120.59%
3Y Avg
-82.59%
5Y Avg
-70.32%
Market Cap
$524770.00
Return on Equity (ROE)
N/A
TTM Avg
617.94%
3Y Avg
178.97%
5Y Avg
105.84%
Market Cap
$552749.00
Return on Equity (ROE)
-66.26%
TTM Avg
77.79%
3Y Avg
-17.48%
5Y Avg
-22.53%
Market Cap
$381940.00
Return on Equity (ROE)
-5.89%
TTM Avg
-13.04%
3Y Avg
-24.95%
5Y Avg
-31.50%
Market Cap
$380715.00
Return on Equity (ROE)
-66.30%
TTM Avg
-86.35%
3Y Avg
-89.49%
5Y Avg
-12.24%
Market Cap
$664522.00
Return on Equity (ROE)
6.58%
TTM Avg
129.48%
3Y Avg
106.12%
5Y Avg
-3462.32%
Market Cap
$242924.00
Return on Equity (ROE)
-287.31%
TTM Avg
-182.19%
3Y Avg
-117.96%
5Y Avg
-131.39%
Market Cap
$812262.00
Return on Equity (ROE)
N/A
TTM Avg
15.66%
3Y Avg
-28.27%
5Y Avg
-26.31%
Market Cap
$812496.00
Return on Equity (ROE)
N/A
TTM Avg
-21.14%
3Y Avg
-26.23%
5Y Avg
-26.18%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| XORTX Therapeutics Inc. (XRTX) | $490141.00 | -68.17% | -120.59% | -82.59% | -70.32% |
| VivoSim Labs, Inc. (VIVS)vs › | $524770.00 | N/A | 617.94% | 178.97% | 105.84% |
| HCW Biologics Inc. (HCWB)vs › | $552749.00 | -66.26% | 77.79% | -17.48% | -22.53% |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | -5.89% | -13.04% | -24.95% | -31.50% |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | -66.30% | -86.35% | -89.49% | -12.24% |
| CDT Equity Inc. (CDT)vs › | $664522.00 | 6.58% | 129.48% | 106.12% | -3462.32% |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | -287.31% | -182.19% | -117.96% | -131.39% |
| Ridgetech, Inc. (RDGT)vs › | $812262.00 | N/A | 15.66% | -28.27% | -26.31% |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $812496.00 | N/A | -21.14% | -26.23% | -26.18% |
| Decoy Therapeutics Inc. (DCOY)vs › | $840509.00 | -334.41% | -290.71% | -280.75% | -198.19% |
ROE
-68.2%
ROA
-60.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -68.17% |
| 2026-03-31 | -215.46% |
| 2025-12-31 | -127.87% |
| 2025-09-30 | -98.64% |
| 2025-06-30 | -92.80% |
| 2025-03-31 | -36.35% |
| 2024-12-31 | -99.41% |
| 2024-09-30 | -31.04% |
| 2024-06-30 | -52.08% |
| 2024-03-31 | -132.21% |
| 2023-12-31 | -45.38% |
| 2023-09-30 | -115.24% |
| 2023-06-30 | -91.90% |
| 2023-03-31 | -69.67% |
| 2022-12-31 | -139.71% |
| 2022-09-30 | 37.34% |
| 2022-06-30 | -45.46% |
| 2022-03-31 | -21.19% |
| 2021-12-31 | -8.69% |
| 2021-06-30 | -97.56% |
| 2021-03-31 | -78.39% |
| 2020-12-31 | -82.33% |
| 2020-09-30 | -48.05% |
| 2020-06-30 | -42.88% |
| 2020-03-31 | -24.48% |
| 2019-03-31 | -551.58% |
| 2018-09-30 | -839.83% |
| 2018-06-30 | -499.10% |
